Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | EGFRt/19-28z/4-1BBL CAR T cells |
Synonyms | |
Therapy Description |
EGFRt/19-28z/4-1BBL CAR T cells are autologous T-cells engineered to express TNFSF9 (4-1BBL) and a chimeric antigen receptor (CAR) targeting CD19 linked to CD28 and CD3zeta signaling domains as well as a truncated EGFR, which may relieve immunosuppression and enhance cytotoxicity against CD19-expressing tumor cells (NCI Thesaurus). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
EGFRt/19-28z/4-1BBL CAR T cells | CD19 Immune Cell Therapy 62 | EGFRt/19-28z/4-1BBL CAR T cells are autologous T-cells engineered to express TNFSF9 (4-1BBL) and a chimeric antigen receptor (CAR) targeting CD19 linked to CD28 and CD3zeta signaling domains as well as a truncated EGFR, which may relieve immunosuppression and enhance cytotoxicity against CD19-expressing tumor cells (NCI Thesaurus). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03085173 | Phase I | EGFRt/19-28z/4-1BBL CAR T cells | A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies | Active, not recruiting | USA | 0 |